

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY<sup>®</sup>

## EDITORIALS

- Comment: Infected Urine as a Risk Factor  
for Postprostatectomy Wound Infection 143  
JOHN N. KRIEGER, MD

- Infected Urine and Suprapubic Prostatectomy:  
The Urological Equivalent of 'Dirty and Infected' Surgery 145  
BRUCE H. HAMORY, MD

## ORIGINAL ARTICLES

- Infected Urine as a Risk Factor for Postprostatectomy Wound Infection 147  
SANTIAGO RICHTER, MD; RUTH LANG, MD; FRUMA ZUR, PHD; ISRAEL NISSENKORN, MD

- Risk Factors for Nosocomial Bacteremia in a Large Spanish  
Teaching Hospital: A Case-Control Study 150  
ANTONI TRILIA, MD, PHD; JOSEP M. GATELL, MD, PHD; JOSEP MENSA, MD;  
XAVIER LATORRE, MD, PHD; MANUEL ALMELA, MD; ELADIO SORIANO, MD;  
MARIA T. JIMENEZ DE ANTA, MD, PHD; JUAN GARCIA SAN MIGUEL, MD, PHD

- Daily Meatal Care for Prevention of Catheter-Associated Bacteriuria:  
Results Using Frequent Applications of Polyantibiotic Cream 157  
DAVID C. CLASSEN, MD; ROBERT A. LARSEN, MD; JOHN P. BURKE, MD;  
DAVID W. ALLING, MD; LANE E. STEVENS, BS

- Application of Multilocus Enzyme Electrophoresis  
to Epidemiologic Investigations of *Xanthomonas maltophilia* 163  
BARBARA SCHABLE, BS, MARGARITA E. VILLARINO, MD, MPH; MARTIN S. FAVERO, PHD;  
J. MICHAEL MILLER, PHD

## EMPIRICALS

- Protecting Travelers from Typhoid Fever 168  
NALINI RAO, MD, FACP

## STATISTICS FOR HOSPITAL EPIDEMIOLOGY

- Statistical Analysis of Stratified 2 X 2 Tables 173  
CHARLES S. DAVIS, PHD

## SPECIAL REVIEW

- Nosocomial Transmission and Infection Control Aspects of Parasitic and  
Ectoparasitic diseases. Part III. Ectoparasites/Summary and Conclusions 179  
LUDWIG A. LETTAU, MD, MPH

## READERS' FORUM

- Benzalkonium Chloride Is Still in Use 186  
LEIGH G. DONOWITZ, MD

- LETTERS TO THE EDITOR 139

- SHEA NEWSLETTER 189

- BOOK REVIEWS 191

From SmithKline Biologicals

 20 mcg/mL  
**Engerix-B<sup>®</sup>**

Hepatitis B Vaccine (Recombinant)

Choice of dosing regimens

**Alternate 0, 1, 2 month dosing regimen for certain populations\***

20 mcg recombinant dose

**Helps to ensure immune response in adult patients of all ages**

	Engerix-B <sup>®</sup>	Recombivax HB <sup>®†</sup>
Adult dose (mcg)	20	10
Standard dosing regimen (0, 1 and 6 months)	✓	✓
Alternate 0, 1, 2 month dosing regimen for certain populations*	✓	
Published efficacy data: Neonates born of 'infected mothers'	✓	✓
VACTRAC TM-computer software for vaccination tracking and compliance	✓	
Bar-coded, unit-dose vials	✓	

**Protection Against Infection**

## **Lowest Cost Per Dose**


**Extensively tested and well tolerated<sup>†</sup>**

**State-of-the-art recombinant technology**

**14 million doses distributed in over 87 countries<sup>‡</sup>**

## **Switch to Engerix-B**

**Can be used to complete a course of vaccination initiated with another hepatitis B vaccine<sup>3,4</sup>**



<sup>†</sup>Hepatitis B Vaccine (Recombinant), MSD.

<sup>‡</sup>Please see brief summary of prescribing information on adjacent page for a complete listing of adverse reactions, contraindications, warnings and precautions.

©SmithKline Beecham, 1990

## Engerix-B®

Hepatitis B Vaccine (Recombinant)

See complete prescribing information in SmithKline Beecham Pharmaceuticals literature or PDR. The following is a brief summary.

**INDICATIONS AND USAGE:** 'Engerix-B' is indicated for immunization against infection caused by all known sub-type of hepatitis B virus. Immunization is recommended in persons of all ages, especially those who are, or will be, at increased risk of exposure to hepatitis B virus.

**CONTRAINDICATIONS:** Hypersensitivity to yeast or any other component of the vaccine is a contraindication for use of the vaccine.

**WARNINGS:** Do not give additional injections to patients experiencing hypersensitivity after an 'Engerix-B' injection. (See CONTRAINDICATIONS.)

Hepatitis B has a long incubation period. Hepatitis B vaccination may not prevent hepatitis B infection in individuals who had an unrecognized hepatitis B infection at the time of vaccine administration. Additionally, it may not prevent infection in individuals who do not achieve protective antibody titers.

**PRECAUTIONS: General:** As with any percutaneous vaccine, keep epinephrine available for use in case of anaphylaxis or anaphylactoid reaction.

As with any vaccine, delay administration, if possible, in persons with any febrile illness or active infection.

**Pregnancy:** Pregnancy Category C: Animal reproduction studies have not been conducted with 'Engerix-B'. It is also not known whether 'Engerix-B' can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Give 'Engerix-B' to a pregnant woman only if clearly needed.

**Nursing Mothers:** It is not known whether 'Engerix-B' is excreted in human milk. Because many drugs are excreted in human milk, use caution when giving 'Engerix-B' to a nursing woman.

**Pediatric Use:** 'Engerix-B' has been shown to be well tolerated and highly immunogenic in infants and children of all ages. Newborns also respond well; maternally transferred antibodies do not interfere with the active immune response to the vaccine.

**ADVERSE REACTIONS:** 'Engerix-B' is generally well tolerated. During clinical studies involving over 10,030 individuals distributed over all age groups, no serious adverse reactions attributable to vaccine administration were reported. As with any vaccine, however, it is possible that expanded commercial use of the vaccine could reveal rare adverse reactions not observed in clinical studies.

Ten double-blind studies involving 2,262 subjects showed no significant difference in the frequency or severity of adverse experiences between 'Engerix-B' and plasmaderived vaccines. In 36 clinical studies a total of 13,495 doses of 'Engerix-B' were administered to 5,071 healthy adults and children who were initially seronegative for hepatitis B markers, and healthy neonates. All subjects were monitored for 4 days post-administration. Frequency of adverse experiences tended to decrease with successive doses of 'Engerix-B'. Using a symptom checklist, the most frequently reported adverse reactions were injection site soreness (22%), and fatigue (14%). Other reactions are listed below:

**Incidence 1% to 19% of Injections:** Induration; erythema; swelling; fever (>37.5°C); headache; dizziness.

\*Parent or guardian completed forms for children and neonates. Neonatal checklist did not include headache, fatigue or dizziness.

**Incidence <1% of Injections:** Pain; pruritus; ecchymosis; sweating; malaise; chills; weakness; flushing; tingling; hypotension; influenza-like symptoms; upper respiratory tract illnesses; nausea; anorexia; abdominal pain/cramps; vomiting; constipation; diarrhea; lymphadenopathy; pain/stiffness in arm, shoulder or neck; arthralgia; myalgia; back pain; rash; urticaria; petechiae; erythema; somnolence; insomnia; irritability; agitation.

Additional adverse experiences have been reported with the commercial use of 'Engerix-B' outside the United States. Those listed below are to serve as alerting information to physicians: Anaphylaxis; erythema multiforme including Stevens-Johnson syndrome; angioedema; arthritis; tachycardia/palpitations; bronchospasm including asthma-like symptoms; abnormal liver function tests; migraine; syncope; paresis; neuropathy including hypoesthesia, paresthesia; Guillain-Barre syndrome and Bell's palsy; transverse myelitis; thrombocytopenia; eczema; purpura; herpes zoster; vertigo; conjunctivitis; keratitis; visual disturbances.

**Potential Adverse Experiences:** In addition, certain other adverse experiences not observed with 'Engerix-B' have been reported with Heptavax-B\*† and/or Recombivax HB\*‡. Those listed below are to serve as alerting information to physicians: Optic neuritis.

**HOW SUPPLIED:** 20 mcg/mL in Single-Dose Vials in packages of 1, 10 and 25 vials.

NDC 5916086041 (package of 1)

NDC 58160-860-11 (package of 10)

NDC 58160-860-16 (package of 25)

10 mcg/0.5 mL in Single-Dose Vials in packages of 1 vial.

NDC 58160-859-01 (package of 1)

†plasma-derived, Hepatitis B Vaccine, MSD.

‡yeast-derived, Hepatitis B Vaccine, MSD.

Manufactured by SmithKline □ lolocalcs, Rixensart,

Belgium

Distributed by SmithKline □ eecham Pharmaceuticals,

Philadelphia, PA19101

Date of issuance Sept. 1990

BRS-EB:LBA

©SmithKline Beecham, 1990

Engerix-B is a registered trademark of SmithKline Beecham.

### References:

1. Poovorawan Y, Sanpavat S, Pongpunlert W, et al: Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. *JAMA* 1989; 261(22):3278-3281.
2. Based on Medi-Span® Hospital Formulary Pricing Guide, December 1990.
3. Data on file, SmithKline Beecham Pharmaceuticals.
4. Bush L, Moon-sammy G, Boscia J: Evaluation of initiating a hepatitis B vaccination schedule with one vaccine and completing it with another. *Hepatology* 1989;10:689.



## UNTIL WE FIND A CURE, THIS IS THE BEST MEDICINE.

You know what they say about laughter. About sunshine. And about love.

Thousands of children with neuromuscular diseases know, too — thanks to special summer camps sponsored by the Muscular Dystrophy Association.

Each summer, MDA camps provide a special outdoor world-without-barriers to children disabled by neuromuscular disorders. Despite leg braces and wheelchairs, these children swim and fish. They go boating. They horseback ride. They have cookouts and crafts. And each youngster shares a special friendship with a volunteer counselor who works one-on-one with the child.

Summer camps are just one way MDA serves patients with neuromuscular diseases. The Association also maintains some 230 clinics around the country to provide essential services like diagnosis, medical follow-up, physical therapy and counseling. And MDA provides orthopedic equipment and other aids for daily living, all free of charge to the patient and his family.

MDA receives no government grants or fees for services — its programs are funded entirely by private donations. For thousands of patients with neuromuscular diseases, you can be the best medicine. Please send a tax-deductible contribution today.

## MDA®

Muscular Dystrophy Association  
Jerry Lewis, National Chairman

To make a donation or request to MDA,  
to receive an annual report or to obtain  
more information, write to:

Muscular Dystrophy Association,  
810 Seventh Avenue, New York, NY 10019.  
Or contact your local MDA office.

MDA® is a registered service mark of Muscular Dystrophy Association, Inc.

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

## CONTENTS

### EDITORIALS

Comment: Infected Urine as a Risk Factor for Postprostatectomy Wound Infection 143

JOHN N. KRIEGER, MD

Infected Urine and Suprapubic Prostatectomy: The Urological  
Equivalent of 'Dirty and Infected' Surgery 145

BRUCE H. HAMORY, MD

### ORIGINAL ARTICLES

Infected Urine as a Risk Factor for Postprostatectomy Wound Infection 147

SANTIAGO RICHTER, MD; Ruth LANG, MD; FRUMA ZUR, PHD; ISRAEL NISSENKORN, MD

Risk Factors for Nosocomial Bacteremia in a Large Spanish Teaching Hospital:  
A Case-Control Study 150

ANTONI Trilla, MD, PHD; JOSEP M. GATELL, MD, PHD; JOSEP MENSA, MD;

XAVIER Latorre, MD, PHD; MANUEL ALMELA, MD; ELADIO SORIANO, MD;

Maria T. JIMENEZ DE ANTA, MD, PHD; JUAN GARCIA SAN MIGUEL, MD, PHD

Daily Meatal Care for Prevention of Catheter-Associated Bacteriuria: Results  
Using Frequent Applications of Polyantibiotic Cream 157

DAVID, C. CLASSEN, MD; ROBERTA. LARSEN, MD; JOHN P. BURKE, MD; DAVID W. ALLING, MD;  
LANE E. %-EVENS, BS

Application of Multilocus Enzyme Electrophoresis to  
Epidemiologic Investigations of *Xanthomonas maltophilia* 163

BARBARA SCHABLE, BS; MARGARITA E. VILLARINO, MD, MPH; MARTIN S. FAVERO, PHD;

J. MICHAEL MILLER, PHD

### EMPORIATRICS

Protecting Travelers from Typhoid Fever 168

NALINI RAO, MD, FACP

### STATISTICS FOR HOSPITAL EPIDEMIOLOGY

Statistical Analysis of Stratified 2 x 2 Tables 173

CHARLES S. DAVIS, PHD

### SPECIAL REVIEW

Nosocomial Transmission and Infection Control Aspects of Parasitic and  
Ectoparasitic Diseases. Part III. Ectoparasites/Summary and Conclusions 179

LUDWIG A. Lettau, MD, MPH

LETTERS TO THE EDITOR 139

READERS' FORUM 186

SHEA NEWSLETTER 189

BOOK REVIEWS 191

CALENDAR OF EVENTS C3

THE PUBLICATION OF ADVERTISING IN THE JOURNAL DOES NOT CONSTITUTE ANY GUARANTEE OR ENDORSEMENT BY THE SOCIETY FOR HOSPITAL EPIDEMIOLOGY OF AMERICA OR SLACK INCORPORATED OF THE ADVERTISED PRODUCT OR SERVICE OR OF CLAIMS MADE BY THE ADVERTISER. THE PUBLICATION OF ARTICLES AND OTHER EDITORIAL MATERIAL IN THE JOURNAL DOES NOT NECESSARILY REPRESENT THE POLICY RECOMMENDATIONS OR ENDORSEMENT BY THE SOCIETY.

**PUBLISHER:** Infection Control and Hospital Epidemiology (ISSN-0899-823X) is published exclusively by SLACK Incorporated 12 times a year. Address: 6900 Grove Rd., Thorofare, NJ 08086. Telephone: (609) 848-1000.

**COPYRIGHT 1991** by The Society for Hospital Epidemiology of America, Inc. and SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

**SUBSCRIPTIONS:** Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Incorporated, 4-22-11, Kitakasai, Edogawaku, Tokyo 134, Japan. Subscription rates in the United States and possessions: Individual: One year-\$70.00; Two years-\$105.00; Three years-\$135.00; Institutional: One year-\$80.00; Two years-\$120.00; Three years-\$160.00. Canada: \$18.00 additional each year; all other countries: \$36.00 additional each year. Single copies of current issues may be obtained for \$8.00, United States and possessions; \$16.00 all other countries.

**REPRINTS:** All requests to reprint or use material published herein should be addressed to Lester J. Robeson, SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086. For reprint orders and prices, contact Fran Micalletti at (609) 848-1000. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of \$1.00 per copy, plus \$.15 per page is paid directly to Copyright Clearance Center, 27 Congress St., Salem, MA 01970. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.

**CHANGE OF ADDRESS:** Notice should be sent to the publisher six weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Secondclass postage is paid at Thorofare, New Jersey 08086, and additional entry points. **POSTMASTER:** Send address changes to SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086.

As of Volume 1, Number 1, INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in Index Medicus, Current Contents-Clinical Practice, Hospital Literature Index, Cumulative Index to Nursing and Allied Health Literature, and Nursing Abstracts.



**EDITORIAL OFFICES**

Vanderbilt University School of Medicine  
 A-1131 Medical Center North  
 Nashville, TN 37232-2637  
 (615) 343-1095; (615) 343-1882 (FAX)  
 Email: iche@mcmail.vanderbilt.edu

**EDITOR**

Michael D. Decker, MD, MPH

**MANAGING EDITOR**

Susan Cantrell

**STATISTICAL EDITOR**

Beverly G. Mellen, PhD

**SENIOR ASSOCIATE EDITORS**

C. Glen Mayhall, MD

Gina Pugliese, RN, MS

William Schaffner, MD

**ASSOCIATE EDITORS**

Donald A. Goldmann, MD

Didier Pittet, MD, MS

Andreas Widmer, MD, MS

**SECTION EDITORS****Beyond Infection Control:****The New Hospital Epidemiology**

Bryan P. Simmons, MD

Stephen B. Kritchevsky, PhD

Memphis, Tennessee

Wing Hong Seto, MD

Hong Kong

**Disinfection and Sterilization**

William A. Rutala, PhD, MPH

Chapel Hill, North Carolina

**Emerging Infectious Diseases**

Larry J. Strausbaugh, MD

Portland, Oregon

Robert W. Pinner, MD

Atlanta, Georgia

**From the Laboratory**

Marcus Zervos, MD

Royal Oak, Michigan

Fred C. Tenover, PhD

Atlanta, Georgia

**Information Management**

John A. Sellick, DO

Buffalo, New York

**The International Perspective**

Mary D. Nettleman, MD, MS

Richmond, Virginia

**Issues in Surgery**

James T. Lee, MD, PhD

St. Paul, Minnesota

**Medical News**

Gina Pugliese, RN, MS

Chicago, Illinois

Martin S. Favero, PhD

Irvine, California

**Practical Healthcare Epidemiology**

Loreen A. Herwaldt, MD

Iowa City, Iowa

**SHEA News**

Murray D. Batt, MD

Clarksburg, West Virginia

**Statistics for Hospital Epidemiology**

David Birnbaum, PhD, MPH

Sidney, British Columbia, Canada

**Topics in Long-Term Care**

Philip W. Smith, MD

Omaha, Nebraska

**Topics in Occupational Medicine**

David Weber, MD, MPH

Chapel Hill, North Carolina

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY<sup>®</sup>

**EDITORIAL ADVISORY BOARD**

- Jacques F. Acar, MD Paris, France  
 J. Wesley Alexander, MD Cincinnati, Ohio  
 Paul Arnow, MD Chicago, Illinois  
 Graham A.J. Ayliffe, MD Birmingham, United Kingdom  
 Neil L. Barg, MD Yakima, Washington  
 Elizabeth Ann Bolyard, RN, MPH, CIC Atlanta, Georgia  
 John M. Boyce, MD Providence, Rhode Island  
 Professor Dr. Ilja Braveny Munich, Federal Republic of Germany  
 Charles Bryan, MD Columbia, South Carolina  
 Christian Brun-Buisson, MD Creteil, France  
 Donald E. Craven, MD Boston, Massachusetts  
 Sue Crow, MSN, RN, CIC Shreveport, Louisiana  
 Franz Daschner, MD Freiburg, Federal Republic of Germany  
 Leigh G. Donowitz, MD Charlottesville, Virginia  
 Charles E. Edmiston, Jr., PhD Milwaukee, Wisconsin  
 Theodore C. Eickhoff, MD Denver, Colorado  
 Bruce Farber, MD Manhasset, New York  
 Victoria J. Fraser, MD St. Louis, Missouri  
 Peter C. Fuchs, MD, PhD Black Butte, Oregon  
 Richard A. Garibaldi, MD Farmington, Connecticut  
 Velvl Greene, PhD, MPH Beer Sheva, Israel  
 Robert Gaynes, MD Atlanta, Georgia  
 David W. Gregory, MD Nashville, Tennessee  
 David K. Henderson, MD Bethesda, Maryland  
 Peter N.R. Heseltine, MD Los Angeles, California  
 Karen Hoffmann, RN, CIC, MS Chapel Hill, North Carolina  
 Marguerite McMillan Jackson, RN, PhD San Diego, California  
 Janine Jagger, MPH, PhD Charlottesville, Virginia  
 William R. Jarvis, MD Atlanta, Georgia  
 Douglas S. Kernodle, MD Nashville, Tennessee  
 Robert H. Latham, MD Nashville, Tennessee  
 Lewis B. Lefkowitz, MD Nashville, Tennessee  
 Hsieh-Shong Leu, MD, MSc Taipei, Taiwan  
 Jack Levy, MD Brussels, Belgium  
 Victor Lorian, MD Bronx, New York  
 Dennis G. Maki, MD Madison, Wisconsin  
 Professor Dr. Walter Marget Munich, Federal Republic of Germany  
 William J. Martone, MD Bethesda, Maryland  
 Allison McGeer, MD Toronto, Ontario, Canada  
 John E. McGowan, Jr., MD Atlanta, Georgia  
 Jonathan L. Meakins, MD, DSc Montreal, Quebec, Canada  
 Raf Mertens, MD Brussels, Belgium  
 Robert R. Muder, MD Pittsburgh, Pennsylvania  
 Joseph M. Mylotte, MD, CIC Buffalo, New York  
 Lindsay Nicolle, MD Winnipeg, Manitoba, Canada  
 Juhani Ojajarvi, MD Helsinki, Finland  
 Michael T. Osterholm, PhD, MPH Minneapolis, Minnesota  
 Jan Evans Patterson, MD San Antonio, Texas  
 Sindy M. Paul, MD Trenton, New Jersey  
 Michael A. Pfaller, MD Iowa City, Iowa  
 Samuel Ponce de Leon, MD, MSc Mexico City, Mexico  
 Isaam Raad, MD Houston, Texas  
 Manfred L. Rotter, MD, DipBact Vienna, Austria  
 Theodore Sacks, MD Jerusalem, Israel  
 William E. Scheckler, MD Madison, Wisconsin  
 Kent Sepkowitz, MD New York City, New York  
 Denis Spelman, MD Prahran Victoria, Australia  
 Michael L. Tapper, MD New York, New York  
 Clyde Thornsberry, PhD Brentwood, Tennessee  
 Professor Leonid P. Titov Minsk, Republic of Belarus  
 Timothy R. Townsend, MD Millwood, Virginia  
 Antoni Trilla, MD, PhD Barcelona, Spain  
 Professor Wang Shu-Qun Beijing, People's Republic of China  
 J. John Weems, Jr., MD Greenville, South Carolina  
 Robert A. Weinstein, MD Chicago, Illinois  
 Professor Dr. W. Weuffen Greifswald, Federal Republic of Germany  
 Sergio B. Wey, MD São Paulo, Brazil  
 Rebecca Wurtz, MD Evanston, Illinois

**SLACK Incorporated**

6900 Grove Road  
 Thorofare, New Jersey 08086  
 (609) 848-1000

**Vice President/Group Publisher**

Richard N. Roash

**Publisher**

John C. Carter

**Editorial Director**

Jennifer Kilpatrick

**Production Editor**

Shirley P. Strunk, ELS

**Assistant Editor**

Eileen C. Anderer

**Circulation Manager**

Lester J. Robeson, CCCC

**Production Director**

Christine Malin

**Production Coordinator**

Joanne Patterson

**Publishing Director/ Advertising**

Wayne McCourt

**Pharmaceutical Group Sales Director**

Michael LoPresti

**Advertising Sales Representative**

Jennine Kane

**Classified/Recruitment Sales Manager**

Michele Burch

# "Synergism.."

Synergism is the working relationship between two ingredients which results in performance superior to that achieved by each ingredient working separately.

Synergism is Sporicidin. Glutaraldehyde combined with an alkaline phenate system produces superior disinfecting properties.\* Patented Sporicidin disinfects with substantially less glutaraldehyde than other products.

Synergism makes Sporicidin tuberculocidal in only ten minutes at room temperature, 68° F and above, when diluted 1:16. Other alkaline glutaraldehyde products cannot be diluted and/or require longer contact times with heating to 77° F.

Sporicidin fulfills the CDC definition of high level disinfection using the lowest concentration of glutaraldehyde... because of Synergism.

\* *Journal of Clinical Microbiology*,  
November 1985, p. 735 - 739



**Sporicidin**  
INTERNATIONAL

12000 Old Georgetown Road, Rockville, Maryland 20847